RU2679920C2 - Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р - Google Patents

Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р Download PDF

Info

Publication number
RU2679920C2
RU2679920C2 RU2015156628A RU2015156628A RU2679920C2 RU 2679920 C2 RU2679920 C2 RU 2679920C2 RU 2015156628 A RU2015156628 A RU 2015156628A RU 2015156628 A RU2015156628 A RU 2015156628A RU 2679920 C2 RU2679920 C2 RU 2679920C2
Authority
RU
Russia
Prior art keywords
antibody
once
asi
amino acid
acid sequence
Prior art date
Application number
RU2015156628A
Other languages
English (en)
Russian (ru)
Other versions
RU2015156628A3 (enExample
RU2015156628A (ru
Inventor
Нейл ШТАЛЬ
Джеми М. Оренго
Эндрю Дж. МЕРФИ
Намита ГАНДХИ
Нейл ГРЭХЕМ
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of RU2015156628A publication Critical patent/RU2015156628A/ru
Publication of RU2015156628A3 publication Critical patent/RU2015156628A3/ru
Application granted granted Critical
Publication of RU2679920C2 publication Critical patent/RU2679920C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
RU2015156628A 2013-06-04 2014-06-03 Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р RU2679920C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361830919P 2013-06-04 2013-06-04
US61/830,919 2013-06-04
PCT/US2014/040695 WO2014197470A1 (en) 2013-06-04 2014-06-03 Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019103601A Division RU2789047C2 (ru) 2013-06-04 2014-06-03 Способы лечения аллергии и повышения эффективности аллерген- специфической иммунотерапии путем введения ингибитора ил-4р

Publications (3)

Publication Number Publication Date
RU2015156628A RU2015156628A (ru) 2017-07-14
RU2015156628A3 RU2015156628A3 (enExample) 2018-05-30
RU2679920C2 true RU2679920C2 (ru) 2019-02-14

Family

ID=51023185

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015156628A RU2679920C2 (ru) 2013-06-04 2014-06-03 Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р

Country Status (25)

Country Link
US (5) US10392439B2 (enExample)
EP (2) EP3004166B1 (enExample)
JP (6) JP6499167B2 (enExample)
KR (3) KR102355114B1 (enExample)
CN (3) CN117982639A (enExample)
AU (3) AU2014275094C1 (enExample)
CA (1) CA2914203C (enExample)
CY (1) CY1124095T1 (enExample)
DK (1) DK3004166T3 (enExample)
ES (1) ES2767080T3 (enExample)
HR (1) HRP20200185T1 (enExample)
HU (1) HUE048655T2 (enExample)
IL (3) IL312710B1 (enExample)
LT (1) LT3004166T (enExample)
MX (2) MX384112B (enExample)
NZ (1) NZ630183A (enExample)
PL (1) PL3004166T3 (enExample)
PT (1) PT3004166T (enExample)
RS (1) RS59883B1 (enExample)
RU (1) RU2679920C2 (enExample)
SG (3) SG10201913835XA (enExample)
SI (1) SI3004166T1 (enExample)
TW (3) TWI755763B (enExample)
WO (1) WO2014197470A1 (enExample)
ZA (1) ZA201508174B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2838943C1 (ru) * 2019-12-20 2025-04-24 Интервет Интернэшнл Б.В. Антитела к собачьему альфа-рецептору интерлейкина-4
US12545738B2 (en) 2019-12-20 2026-02-10 Intervet Inc. Canine interleukin-4 receptor alpha antibodies

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017220184B2 (en) * 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
MX390517B (es) * 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
KR20230041834A (ko) 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
US11771743B2 (en) * 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
KR102513485B1 (ko) * 2016-09-16 2023-03-23 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CN119492842A (zh) 2016-10-25 2025-02-21 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
CN118416215A (zh) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
US11460452B2 (en) 2017-12-13 2022-10-04 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
CA3096582A1 (en) * 2018-04-25 2019-12-05 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmr.beta. antibodies
TWI903214B (zh) 2018-05-02 2025-11-01 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
MX2021002971A (es) * 2018-09-14 2021-05-12 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CN113166259A (zh) 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
WO2020135710A1 (zh) * 2018-12-27 2020-07-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
RU2700788C1 (ru) * 2019-01-17 2019-09-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ оценки эффективности проведения аллерген-специфической иммунотерапии при аллергическом рините
EP3934620A1 (en) 2019-03-05 2022-01-12 Regeneron Pharmaceuticals, Inc. Human serum albumin in formulations
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
WO2021102186A1 (en) * 2019-11-20 2021-05-27 Aimmune Therapeutics, Inc. Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drug
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
WO2022015049A1 (ko) * 2020-07-17 2022-01-20 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도
MX2023007945A (es) * 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
WO2023009437A1 (en) * 2021-07-26 2023-02-02 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047331A2 (en) * 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2010053751A1 (en) * 2008-10-29 2010-05-14 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
BR9205967A (pt) 1991-05-03 1994-07-26 Seragen Inc Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
AU766492B2 (en) 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001267917A1 (en) 2000-07-26 2002-02-05 Kenjirou Tsuchida Antipruritic compositions and compositions promoting wound healing
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1592777A4 (en) 2003-02-01 2008-06-04 Tanox Inc METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20110301046A1 (en) 2008-12-01 2011-12-08 Children's Hospital Medical Center Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
BR112012005117A2 (pt) 2009-09-07 2016-05-03 Dbv Tech método de tratamento de esofagite eosinofílica
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
ES2894936T3 (es) 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US20140303067A1 (en) 2011-10-06 2014-10-09 N.V. Nutricia Treatment of eosinophilic esophagitis
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102576903B1 (ko) * 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047331A2 (en) * 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2010053751A1 (en) * 2008-10-29 2010-05-14 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRUNEWALD S.M. et al. "An Antagonistic IL-4 Mutant Presents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor System Completely Abrogates Humoral Immune Response to Allergem and Development of Allergic Symptoms In Vivo". Journal of Immunology, The American Assotciation of Immunologists, 1998;160:4004-4009. *
Sanofi and regeneration report positive proof-of-concept data for dupilumab, an IL-4R alpha antibody, in atopic dermatitis. 2013, Mar,2/, pp. 1-3. *
РОМАНЮК Л.И. "Аллерген-специфическая иммунотерапия: механизмы, методы, эффективность". Клiнiчна iмунологiя Аддергологiя Iнфектологiя, 2012, специальный номер, с.44-47, найдено 25.05.2018 из Интернет:https://kiai.com.ua/ru-issue-article-772/. *
РОМАНЮК Л.И. "Аллерген-специфическая иммунотерапия: механизмы, методы, эффективность". Клiнiчна iмунологiя Аддергологiя Iнфектологiя, 2012, специальный номер, с.44-47, найдено 25.05.2018 из Интернет:https://kiai.com.ua/ru-issue-article-772/. GRUNEWALD S.M. et al. "An Antagonistic IL-4 Mutant Presents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor System Completely Abrogates Humoral Immune Response to Allergem and Development of Allergic Symptoms In Vivo". Journal of Immunology, The American Assotciation of Immunologists, 1998;160:4004-4009. Sanofi and regeneration report positive proof-of-concept data for dupilumab, an IL-4R alpha antibody, in atopic dermatitis. 2013, Mar,2/, pp. 1-3. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2838943C1 (ru) * 2019-12-20 2025-04-24 Интервет Интернэшнл Б.В. Антитела к собачьему альфа-рецептору интерлейкина-4
RU2840044C1 (ru) * 2019-12-20 2025-05-15 Интервет Интернэшнл Б.В. Антитела к собачьему альфа-рецептору интерлейкина-4
US12545738B2 (en) 2019-12-20 2026-02-10 Intervet Inc. Canine interleukin-4 receptor alpha antibodies

Also Published As

Publication number Publication date
JP6499167B2 (ja) 2019-04-10
JP2025011257A (ja) 2025-01-23
HRP20200185T1 (hr) 2020-05-01
MX2021002173A (es) 2021-04-28
US20180094070A1 (en) 2018-04-05
HK1216898A1 (en) 2016-12-09
TW201519905A (zh) 2015-06-01
SG11201509044QA (en) 2015-12-30
AU2014275094B2 (en) 2019-03-28
IL312710B1 (en) 2026-04-01
RS59883B1 (sr) 2020-03-31
SG10201709670XA (en) 2018-01-30
WO2014197470A1 (en) 2014-12-11
JP2020193218A (ja) 2020-12-03
IL312710A (en) 2024-07-01
JP2022101613A (ja) 2022-07-06
AU2014275094C1 (en) 2019-10-10
EP3004166A1 (en) 2016-04-13
KR20230017923A (ko) 2023-02-06
ES2767080T3 (es) 2020-06-16
NZ630183A (en) 2018-10-26
IL273678B1 (en) 2024-06-01
LT3004166T (lt) 2019-12-27
CN117982639A (zh) 2024-05-07
SI3004166T1 (sl) 2020-02-28
US20230159647A1 (en) 2023-05-25
JP7575526B2 (ja) 2024-10-29
SG10201913835XA (en) 2020-03-30
TW202038999A (zh) 2020-11-01
TW201906630A (zh) 2019-02-16
JP2016521713A (ja) 2016-07-25
JP7061163B2 (ja) 2022-04-27
JP2019112440A (ja) 2019-07-11
KR102580468B1 (ko) 2023-09-21
AU2014275094A1 (en) 2015-12-17
MX384112B (es) 2025-03-14
RU2019103601A (ru) 2019-03-12
US20200299393A1 (en) 2020-09-24
KR102355114B1 (ko) 2022-01-27
EP3004166B1 (en) 2019-11-20
CA2914203C (en) 2024-04-16
JP2023103389A (ja) 2023-07-26
CY1124095T1 (el) 2022-03-24
HUE048655T2 (hu) 2020-08-28
AU2021229250B2 (en) 2024-11-14
JP6754857B2 (ja) 2020-09-16
EP3617233A1 (en) 2020-03-04
PL3004166T3 (pl) 2020-06-01
AU2021229250A1 (en) 2021-10-07
AU2019204577B2 (en) 2021-06-24
US10669341B2 (en) 2020-06-02
MX2015016473A (es) 2016-03-03
AU2019204577A1 (en) 2019-07-18
CN118001391A (zh) 2024-05-10
US20140356372A1 (en) 2014-12-04
US20180094069A1 (en) 2018-04-05
IL242456B (en) 2020-04-30
TWI697334B (zh) 2020-07-01
IL273678B2 (en) 2024-10-01
US10676530B2 (en) 2020-06-09
KR20160014626A (ko) 2016-02-11
PT3004166T (pt) 2020-01-14
RU2015156628A3 (enExample) 2018-05-30
IL273678A (en) 2020-05-31
CA2914203A1 (en) 2014-12-11
ZA201508174B (en) 2017-09-27
RU2015156628A (ru) 2017-07-14
TWI633891B (zh) 2018-09-01
US11485788B2 (en) 2022-11-01
TWI755763B (zh) 2022-02-21
KR102492826B1 (ko) 2023-01-30
DK3004166T3 (da) 2020-01-06
US10392439B2 (en) 2019-08-27
JP7284313B2 (ja) 2023-05-30
KR20220011810A (ko) 2022-01-28
CN105377894A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
JP7575526B2 (ja) Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP7659500B2 (ja) アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ
RU2789047C2 (ru) Способы лечения аллергии и повышения эффективности аллерген- специфической иммунотерапии путем введения ингибитора ил-4р
HK40022146A (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
HK1216898B (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor